Released May 5, 2017, after the close
10-Q filed May 8, 2017, 38 days after period end · 0001171843-17-002748
Q1 2017 · 10-Q
Revenue$18.09M$18.09M −32.9% vs Q1 2016−31.5% vs Q4 2016
Net Income-$1.07M-$1.07M N/M vs Q1 2016N/M vs Q4 2016
EPS Diluted-$0.03-$0.03 N/M vs Q1 2016N/M vs Q4 2016
Gross Profit$9,577,000−26.0%
Operating Income-$350,000N/M
Operating Cash Flow-$610,000N/M
Free Cash Flowderived-$808,000—
Margins · derived
Gross margin53.0%+4.9 pt vs Q1 2016
Operating margin-1.9%−1.1 pt vs Q1 2016
Net margin-5.9%−3.5 pt vs Q1 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2017 | Q1 2016 | Q1 2015 | Q1 2014 |
|---|---|---|---|---|
| Revenue | $18.09M | $26.96M | $25.76M | $25.89M |
| Net Income | -$1.07M | -$636.00K | -$1.40M | $719.00K |
| EPS Diluted | -$0.03 | -$0.02 | -$0.04 | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR